Press Release Details

Cerus Corporation to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference

October, 22 2004

CONCORD, Calif. -- Cerus Corporation (Nasdaq:CERS) today announced that Claes Glassell, president and CEO, William J. Dawson, vice president, finance and CFO, and David N. Cook, vice president of research and development, will present on Wednesday, October 27, 2004, at 11:50 a.m. Eastern Time during the Rodman and Renshaw Techvest 6th Annual Healthcare Conference.

Interested parties can access a live or archived Internet broadcast of the presentation at The presentation will be archived for 90 days.

About Cerus

Cerus Corporation is developing novel technologies to provide safer and more effective therapeutic options to patients in areas with substantial unmet medical needs, particularly within the fields of cancer, infectious disease and blood safety. The Concord, California-based company is combining its proprietary vector technologies with public domain and proprietary antigens to develop new therapies for cancer and infectious disease. Cerus has two therapeutic cancer vaccine products in development using its Listeria vector technology, one in collaboration with MedImmune, Inc. and the other with Johns Hopkins University. Cerus is also collaborating with subsidiaries of Baxter International Inc. on the INTERCEPT Blood System, which is designed to enhance the safety of donated blood components by inactivating viruses, bacteria and other pathogens. The INTERCEPT Blood System is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System for platelets is approved for use in the European Union and Canada.

Helinx is a trademark of Cerus Corporation.

Baxter and INTERCEPT are trademarks of Baxter International Inc.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600